103 filings
ARS
2023 FY
TRML
Tourmaline Bio Inc
19 Apr 24
Annual report to shareholders
4:05pm
DEFA14A
TRML
Tourmaline Bio Inc
19 Apr 24
Additional proxy soliciting materials
4:04pm
DEF 14A
TRML
Tourmaline Bio Inc
Definitive proxy
19 Apr 24
4:02pm
S-8
TRML
Tourmaline Bio Inc
19 Mar 24
Registration of securities for employees
5:10pm
10-K
2023 FY
TRML
Tourmaline Bio Inc
Annual report
19 Mar 24
5:02pm
8-K
3d9xa0 spl
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
8-K
4kwy3hdr1juso
26 Jan 24
Other Events
4:12pm
424B5
voqrad
26 Jan 24
Prospectus supplement for primary offering
4:08pm
424B5
1j0c6 x55698
24 Jan 24
Prospectus supplement for primary offering
9:20pm
8-K
qur53u98efj3zf2td
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
jou46adhtmy
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
hwejacxuwzb6lo
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
8-K
o47rgnt37u
30 Nov 23
Departure of Directors or Certain Officers
8:25am
8-K
1ee9zc
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
8-K
ew2vmje8
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
S-8
1cwsnfkyos cd
20 Oct 23
Registration of securities for employees
9:23pm
8-K
lrcer jmo
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
o6yfq6qf9f
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
425
b8xe460 t7dn
10 Oct 23
Business combination disclosure
4:32pm